Login / Signup

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.

Nicholas J VogelzangSumanta K PalSameer R GhateElyse SwallowNanxin LiMiranda PeeplesMiriam L ZichlinMark K MeiselbachJose Ricardo PerezNeeraj Agarwal
Published in: Advances in therapy (2017)
Among elderly Medicare patients with advanced RCC, first-line pazopanib tretament was associated with significantly longer OS, as well as lower healthcare costs and HRU, compared with first-line sunitinib treatment.
Keyphrases